ArticleThe Journal of urology2018
Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Samir S TanejaPubMed ↗Publisher ↗
No numbers read from the abstract.